(Q54461833)

30 May 2018

title

Haemodynamic effects of enalapril, a new converting enzyme inhibitor, in hypertensive patients. (English)

1 reference

30 May 2018

1 reference

1 reference

M Velasco

1

1 reference

30 May 2018

H Silva

2

1 reference

30 May 2018

J Morillo

3

1 reference

30 May 2018

R Pellicer

4

1 reference

30 May 2018

A Ramirez

5

1 reference

30 May 2018

A Urbina

6

1 reference

30 May 2018

O Hernández-Pieretti

7

1 reference

30 May 2018

H J Gómez

8

1 reference

30 May 2018

publication date

1 January 1985

1 reference

30 May 2018

European Journal of Clinical Pharmacology

published in

1 reference

30 May 2018

volume

29

1 reference

30 May 2018

issue

1

1 reference

30 May 2018

page(s)

17-20

1 reference

30 May 2018

Reflex-hemodynamic adjustments and baroreflex sensitivity during converting enzyme inhibition with MK-421 in normal humans

cites work

1 reference

12 December 2020

Application of a radioimmunoassay for angiotensin I to the physiologic measurements of plasma renin activity in normal human subjects

1 reference

12 December 2020

Systolic time intervals in cardiac disease. I

1 reference

12 December 2020

Converting-enzyme inhibitor enalapril (MK421) in treatment of hypertension with renal artery stenosis.

1 reference

12 December 2020

Methods for the investigation of peripheral blood flow

1 reference

12 December 2020

A Comparison of Double-Isotope Derivative and Radioimmunological Estimation of Plasma Aldosterone Concentration in Man

1 reference

12 December 2020

Enalapril (MK421) in the treatment of hypertension with renal artery stenosis

1 reference

12 December 2020

A new class of angiotensin-converting enzyme inhibitors

1 reference

12 December 2020

Converting enzyme inhibition with an orally active compound in hypertensive man

1 reference

12 December 2020

Effect of N-[(S)-1-carboxy-3-phenylpropyl]-L-Ala-L-Pro and its ethyl ester (MK-421) on angiotensin converting enzyme in vitro and angiotensin I pressor responses in vivo

1 reference

12 December 2020

In vivo comparison of three orally active inhibitors of angiotensin-converting enzyme

1 reference

12 December 2020

Antihypertensive activity of N-[(S)-1-(ethoxycarbonyl)-3-phenylpropyl]-L-Ala-L-Pro (MK-421), an orally active converting enzyme inhibitor

1 reference

12 December 2020

Endocrine and Cardiovascular Influences of Converting Enzyme Inhibition with SQ 14225 in Hypertensive Patients in the Supine Position and during Head-Up Tilt before and after Sodium Depletion*

1 reference

12 December 2020

Three new long-acting converting-enzyme inhibitors: Relationship between plasma converting-enzyme activity and response to angiotensin I

1 reference

12 December 2020

Comparative effects of captopril and MK 421 on sympathetic function in spontaneously hypertensive rats

1 reference

12 December 2020

The effect of angiotensin converting enzyme inhibitor on baroreceptor reflexes in conscious dogs during sodium depletion [proceedings]

1 reference

12 December 2020

Antihypertensive Effect of the Oral Angiotensin Converting-Enzyme Inhibitor SQ 14225 in Man

1 reference

12 December 2020

Development and evaluation of an impedance cardiac output system

1 reference

12 December 2020

Captopril in the treatment of clinical hypertension and cardiac failure

1 reference

12 December 2020

Evaluation of impedance cardiac output in children

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF00547362

1 reference

30 May 2018

1 reference

30 May 2018